EVT Innovate: Building bridges between cutting edge science and transformative pharma projects
The EVT Innovate segment focuses on investing and developing Evotec proprietary assets including early-stage discovery programmes as well as more advanced drug candidates. These programmes are referred to as Cure X (usually a specific mechanism) or Target X (usually a single target) programmes according to their scope and breadth and focus in particular on first-in-class projects based on innovative biology and cover a broad range of disease areas like diabetes and diabetic complications, inflammatory diseases, neuroscience, oncology, pain and anti-infectives. Cure X and Target X initiatives are carefully selected, often discovery-stage, projects that are either pursued as internal R&D projects or in collaboration with leading academic laboratories or biotech companies. Preferably, these initiatives pursue drug product opportunities with disease-modifying properties, i.e. mechanisms that may slow or even reverse progression of disease. Cure X / Target X programmes are designed to deliver starting points for strategic pharma alliances or potentially spin-out companies with the goal to advance and these projects to tangible value inflection points and ultimately expand Evotec’s clinical stage pipeline.